ArticleBioresources and bioprocessing2026
Ulvan and Ulva oligosaccharides from Ulva sp. attenuate osteoarthritis in a high-fat diet and ligamentous meniscal injury-induced rat model.
Article in Bioresources and bioprocessing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a chronic joint disease. It is marked by the progressive deterioration of subchondral bone, articular cartilage, and synovium, with obesity acting as a significant risk factor by promoting inflammation and cartilage degradation. Ulvan and Ulva oligosaccharides derived from Ulva sp. seaweed have shown anti-inflammatory properties that may be beneficial in this context. Therefore, the aim of this research was to determine the protective effect of ulvan and Ulva oligosaccharides from Ulva sp. on monosodium iodoacetate (MIA)-induced inflammation in SW1353 cells and in a high-fat-diet/ACL-meniscus-injury rat model of osteoarthritis. The Ulva extract (UE) was hydrolyzed with cellulase to obtain Ulva hydrolysate (UH). The rats were treated using UE (50 mg/kg) and three different doses of UH (UH1, 50 mg/kg; UH2, 100 mg/kg; UH5, 250 mg/kg). In addition, UH contains higher levels of total sugars (22.8 ± 1.3%) and sulfated groups (18.4 ± 0.2%) compared with UE (19.6% and 15.5%, respectively). Treatment with UE and UH significantly reduce matrix metalloproteinase-3 (MMP-3) and interleukin-6 levels and increase collagen type II alpha 1 level in MIA-induced SW1353 cells. The animal study revealed that UE and UH significantly decrease triglyceride (TG), total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C) levels. These treatments also reduced nitric oxide levels in OA rats and inhibited pro-inflammatory cytokines and mediators, MMP-3, and C-terminal cross-linked telopeptides of type II collagen (CTX-II). Additionally, UE and UH treatment reduced proteoglycan loss in cartilage lesions in OA rats after six weeks of treatment. These findings suggest that Ulvan and Ulva oligosaccharides from Ulva sp. may have potential as treatments for osteoarthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.